Business Context and Reporting Period
Pasithea Therapeutics Corp. filed a Form 8-K reporting events occurring on June 21, 2022, with the report signed June 22, 2022. The company is a Nasdaq-listed emerging growth company focused on therapeutics. The filing primarily concerns its acquisition of Alpha-5 integrin, LLC.
Transaction and Key Terms
- Pasithea acquired 100% of the equity interests of Alpha-5 integrin, LLC from PD Joint Holdings, LLC Series 2016-A and Lawrence Steinman. The transaction closed on June 21, 2022.
- Consideration included 3,260,870 shares of Pasithea common stock and 1,000,000 warrants to purchase common stock.
- The sellers may also receive contingent earn-out payments equal to 2% to 4% of net sales from a drug currently under development by Alpha.
- The warrants and shares were issued in an unregistered transaction based on the Securities Act Section 4(a)(2) exemption.
- The sellers received customary representations, warranties, indemnification rights, non-competition and non-solicitation provisions, and registration rights.
- While a seller owns at least 5% of Pasithea’s common stock, that seller is subject to a standstill restricting additional acquisitions of voting or convertible securities without board approval.
- Alpha employees entered into employment agreements with Pasithea.
Financial Metrics, Liquidity, and Capitalization
The filing does not provide revenue, net income, cash flow, margins, debt, liquidity, acquisition accounting, purchase price allocation, or other financial statement amounts. The issuance of 3,260,870 shares and warrants to purchase additional shares will dilute existing shareholders, subject to the terms and exercise of the warrants.
Material Changes and Related-Party Matters
- The acquisition adds Alpha-5 integrin and its drug-development assets to Pasithea’s business.
- Lawrence Steinman, a seller, is Pasithea’s Executive Chairman and Co-Founder and therefore is a related party.
- The transaction was approved by the disinterested members of the Audit Committee and the disinterested members of the Board under the company’s related-party transaction policy.
- Pasithea is required to file a resale registration statement for the issued shares and the shares issuable upon exercise of the warrants and to seek its effectiveness promptly.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or quantified operating outlook. The acquisition includes a development-stage drug and contingent earn-out obligations tied to future net sales, but the filing does not state the drug’s development status, expected launch timing, probability of success, or projected sales.
- Key risks include clinical, regulatory, commercial, and financing uncertainty associated with the acquired development program.
- Future earn-out payments could create additional obligations if the product generates sales.
- Resale registration and potential warrant exercise may increase the public float and create additional dilution or selling pressure.
- The complete terms of the acquisition are contained in the Membership Interest Purchase Agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Review Exhibit 10.1 for the complete purchase price, warrant terms, representations, indemnification provisions, and earn-out mechanics.
- Verify the number of shares outstanding before and after the transaction and the potential dilution from the 1,000,000 warrants.
- Monitor the required resale registration statement and any subsequent sales by the sellers.
- Assess Alpha’s drug-development assets, clinical data, intellectual-property position, regulatory pathway, and funding requirements.
- Review subsequent filings for acquisition accounting, changes in liquidity, related-party disclosures, and any contingent consideration recorded or accrued.